Proteogenomic Monitoring and Assessment of Liver Transplant Recipients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorNorthwestern University
About this trial
This study is being done to test blood, urine and tissue samples to see if this can help decide if CKD (Chronic Kidney Disease), AR (Acute Rejection) and HCV (Hepatitis C Virus) can be identified in its early stages. CKD damage to the kidneys, AR and HCV all lower the body's ability to function properly. Early detection of these conditions could assist with successful treatment and possibly lead to less repeat organ transplants.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Male and female recipients of all races, ≥18 years of age.
Patients undergoing primary or subsequent living or deceased donor liver transplantation.
Subject and/or guardian must be able to provide informed consent.
Subject and/or guardian must be able to comply with the study protocol.
Disqualifiers
None
Trial population
The intention of our biomarker panel is to be broadly applicable to all patients with liver transplant with the assumption that there are common underlying molecular mechanisms of CKD and AR (and HCV) that can be detected hopefully at early stages of disease. We therefore want to validate and test our biomarker panel in a broad collection of patient types.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Proteogenomic Biomarkers for CKD, AR and HCV
To validate specific proteogenomic biomarker panels for CKD and AR (and HCV) in a prospective serial blood and urine monitoring study of liver transplant recipients
Time frame
At time of liver biopsySponsors and contacts
Click on the lead sponsor to view all of their trials.
Northwestern University
Lead sponsor
The Scripps Research Institute
Collaborator
Source ClinicalTrials.gov